- \n
- Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027<\/i><\/li>\n
- On Track to Initiate RESOLVE, a Registrational Phase 2b\/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027<\/i><\/li>\n
- On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026<\/i><\/li>\n
- On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026<\/i><\/li>\n
- Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029<\/i><\/li>\n<\/ul>\n
WATERTOWN, Mass.–(BUSINESS WIRE<\/a>)–Enanta Pharmaceuticals, Inc.<\/a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026.<\/p>\n
\n\u201cDuring the quarter, we continued to build momentum across both our RSV and immunology programs,\u201d said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. \u201cDosing began in LOTUS, our Phase 2b trial of zelicapavir in pediatric patients with RSV in Thailand, with topline data anticipated in 2027. We also announced plans to advance zelicapavir into a registrational Phase 2b\/3 trial in high-risk adults with RSV and remain on track to initiate this study, RESOLVE, in the fourth quarter, with initial Phase 2b data expected next year. With no approved antiviral therapies currently available for RSV, we believe zelicapavir is uniquely positioned to address a substantial unmet need across both high-risk adult and pediatric populations. We continue to execute our clinical development plan and aim to deliver what could become the first approved antiviral treatment for RSV. Additionally, in immunology, we are focused on reporting topline data from our Phase 1 study of EDP-978 in the fourth quarter of 2026, while also advancing EPS-3903, our oral, once-daily STAT6 inhibitor, toward an IND filing this year. Further, we are on track to select an MRGPRX2 development candidate in the second half of 2026. With a catalyst rich year ahead, we have multiple opportunities to drive shareholder value and bring important treatments to patients in need.\u201d<\/p>\n
Fiscal Third Quarter Ended June 30, 2026 Financial Results<\/b><\/p>\n
\nTotal revenue for the three months ended June 30, 2026 was $14.4 million and consisted of royalty revenue from worldwide net sales of AbbVie\u2019s hepatitis C virus (HCV) regimen MAVYRET\u00ae\/MAVIRET\u00ae (glecaprevir\/pibrentasvir), compared to $18.3 million for the three months ended June 30, 2025. The decrease in revenue is primarily due to AbbVie\u2019s lower reported HCV sales as compared to the same period in 2025.<\/p>\n
\nA portion (54.5%) of Enanta\u2019s ongoing royalty revenue from AbbVie\u2019s net sales of MAVYRET\u00ae\/MAVIRET\u00ae is paid to OMERS, one of Canada\u2019s largest defined benefit pension plans, pursuant to a royalty sale transaction affecting royalties earned after June 2023. For financial reporting purposes, the transaction was treated as debt, with the upfront purchase payment of $200.0 million recorded as a liability. Each quarter, Enanta records 100% of the royalty earned as revenue and then amortizes the debt liability proportionally as 54.5% of the cash royalty payments are paid to OMERS through June 30, 2032, subject to a cap of 1.42 times the purchase price, after which point 100% of the cash royalty payments will be retained by Enanta. Interest expense was $4.1 million for the three months ended June 30, 2026, as compared to $1.6 million for the period ended June 30, 2025. The increase was due to the increase in forecasted royalty revenue from AbbVie\u2019s net sales of MAVYRET\u00ae\/MAVIRET\u00ae.<\/p>\n
\nResearch and development expenses totaled $22.1 million for the three months ended June 30, 2026, compared to $27.2 million for the three months ended June 30, 2025. The decrease was due to a decrease in clinical trial expenses for Enanta\u2019s RSV programs, partially offset by increased costs associated with the Company\u2019s immunology programs.<\/p>\n
\nGeneral and administrative expenses totaled $9.5 million for the three months ended June 30, 2026, compared to $10.0 million for the three months ended June 30, 2025. The decrease was primarily due to a decrease in stock-based compensation expenses.<\/p>\n
\nInterest and investment income, net, totaled $1.9 million for the three months ended June 30, 2026, compared to $2.3 million for the three months ended June 30, 2025. The decrease in interest and investment income was due to lower interest rates year over year.<\/p>\n
\nEnanta recorded an income tax expense of less than $0.1 million for the three months ended June 30, 2026 compared to an income tax expense of less than $0.1 million for the three months ended June 30, 2025.<\/p>\n
\nNet loss for the three months ended June 30, 2026 was $19.5 million, or a loss of $0.67 per diluted common share, compared to a net loss of $18.3 million, or a loss of $0.85 per diluted common share, for the corresponding period in 2025.<\/p>\n
\nEnanta\u2019s cash, cash equivalents and short-term and long-term marketable securities totaled $211.5 million at June 30, 2026. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029.<\/p>\n
Virology<\/b><\/p>\n
\nEnanta\u2019s virology pipeline includes the leading portfolio of RSV treatments in clinical development, consisting of zelicapavir, a once-daily N-protein inhibitor, and EDP-323, a once-daily L-protein inhibitor, both of which received Fast Track designation from the U.S. Food and Drug Administration (FDA).<\/p>\n
- \n
- \nDosing began in LOTUS, a Phase 2b study of zelicapavir in pediatric patients with RSV. LOTUS will evaluate zelicapavir in approximately 150 hospitalized and non-hospitalized children aged 28 days to 36 months who test positive for RSV and have experienced symptoms for up to 72 hours. Conducted in collaboration with the Penta Foundation and the AMS-PHPT Research Unit at Chiang Mai University, LOTUS is designed to evaluate the efficacy, safety, and antiviral activity of zelicapavir, with topline data expected in 2027.<\/p>\n<\/li>\n
- \nIn June, Enanta announced its advancement of zelicapavir into registrational development, following an End-of-Phase 2 meeting with the FDA. Advancement into registrational development through a single Phase 2b\/3 trial further highlights zelicapavir\u2019s potential to become the first approved antiviral therapy for RSV and supports Enanta’s continued leadership in RSV drug development.<\/p>\n
- \n
- \nRESOLVE, the registrational Phase 2b\/3 trial of zelicapavir in high-risk adults with RSV is on track to initiate in the fourth quarter of 2026. RESOLVE will enroll adults with RSV who are at high risk of severe disease, including patients aged 75 years or older and those with COPD or congestive heart failure. The Phase 2b portion of RESOLVE is designed to confirm the treatment effect observed in the prior RSVHR study, which demonstrated a clinically meaningful benefit in this high-risk adult population. Topline Phase 2b data from RESOLVE is expected in 2027.<\/p>\n<\/li>\n
- \nEnanta presented data on zelicapavir at the American Thoracic Society (ATS)International Conference 2026 which was held May 15-20, 2026, in Orlando, Florida and at the European Society of Clinical Microbiology & Infectious Diseases (ESCMID) Global Conference 2026 which was held April 17-21, 2026, in Munich, Germany. The posters and presentations are available on the Company\u2019s website here<\/a>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- \nEnanta\u2019s second RSV candidate, EDP-323, can be used alone or in combination with other agents, such as zelicapavir, to potentially broaden the treatment window or addressable patient populations. Previously, the Company reported positive results from a Phase 2a challenge study of healthy adults infected with RSV, in which treatment with EDP-323 achieved highly statistically significant reductions in both viral load and clinical symptoms compared to placebo.<\/p>\n<\/li>\n<\/ul>\n
Immunology<\/b><\/p>\n
\nEnanta\u2019s immunology pipeline is focused on designing and developing highly potent and selective oral inhibitors for the treatment of inflammatory diseases, by targeting key drivers of the type 2 immune response.<\/p>\n
- \n
- \nEnanta\u2019s lead immunology program, EDP-978, is a potent and selective once-daily oral KIT inhibitor in development for the treatment of chronic urticaria and potentially other mast cell-mediated diseases. In April, the Company announced that the first participant was dosed in a randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial. The trial is expected to enroll approximately 98 healthy adult volunteers ranging in age from 18 to 65 years old to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics, including serum tryptase, of EDP-978. The trial includes a single ascending dose phase, with a two-part food-effect cohort, and a multiple ascending dose phase with a 14-day treatment period. The Company expects to report topline data from the trial in the fourth quarter of 2026.<\/p>\n<\/li>\n
- \nEnanta\u2019s second immunology program, EPS-3903, is a novel, potent and selective oral STAT6 inhibitor, in development for the treatment of atopic dermatitis and other diseases currently treated by dupilumab. The Company is currently performing scale-up and IND-enabling activities and is targeting an IND filing in the second half of 2026.<\/p>\n
- \n
- \nEnanta presented posters highlighting data on EPS-3903 at the ATSInternational Conference 2026 which was held May 15-20, 2026, in Orlando, Florida and at the American Association of Immunology Conference (Immunology 2026\u2122) which was held April 15-19, 2026, in Boston, Massachusetts. The posters are available on the Company\u2019s website here<\/a>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- \nEnanta\u2019s third immunology program targets MRGPRX2, a non-canonical G-Protein-Coupled-Receptor (GPCR) expressed predominantly on mast cells, as well as peripheral neurons. Inhibiting MRGPRX2 may have potential to address multiple mast-cell driven diseases, as well as having potential in migraine. Currently, the Company is evaluating multiple compounds in preclinical studies and expects to select a development candidate in the second half of 2026.<\/p>\n<\/li>\n<\/ul>\n
Corporate<\/b><\/p>\n
- \n
- \nIn June, Enanta announced that its partner AbbVie received European Commission approval of MAVIRET\u00ae (glecaprevir\/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged three years and older. MAVIRET is now the only treatment approved in the European Union for both acute and chronic HCV infection. Glecaprevir, one of the two direct-acting antivirals in MAVIRET, was discovered by Enanta and is a source of ongoing royalty revenue for the Company.<\/p>\n<\/li>\n
- \nIn June, the United States Court of Appeals for the Federal Circuit affirmed the summary judgment decision of the United States District Court for the District of Massachusetts in the Company\u2019s suit against Pfizer Inc. and ruled that the claims of U.S. Patent No. 11,358,953 were invalid. In July, the Company filed a combined petition for panel or en banc rehearing of the Federal Circuit\u2019s decision. A hearing for the patent infringement action against Pfizer in the Unified Patent Court (UPC) of the European Union, and Pfizer\u2019s counterclaim for revocation, has been scheduled for September 29, 2026. Enanta expects a decision from the UPC within weeks after the hearing.<\/p>\n<\/li>\n
- \nEnanta plans to issue its fiscal fourth quarter financial results press release on November 16, 2026.<\/p>\n<\/li>\n<\/ul>\n
About Enanta Pharmaceuticals, Inc.<\/b><\/p>\n
\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta\u2019s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company\u2019s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.<\/p>\n
\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). A portion of Enanta\u2019s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta\u2019s operations. Please visit www.enanta.com<\/a> for more information.<\/p>\n
Forward-Looking Statements<\/b><\/p>\n
\nThis press release contains forward-looking statements, including statements with respect to the timeline and prospects for advancement of Enanta\u2019s clinical programs in RSV and KIT inhibition and its preclinical immunology programs, including its programs targeting STAT6 and MRGPRX2 inhibition. Statements that are not historical facts are based on management\u2019s current expectations, estimates, forecasts and projections about Enanta\u2019s business and the industry in which it operates and management\u2019s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; the discovery and development risks of Enanta\u2019s programs in virology and immunology; Enanta\u2019s limited clinical development experience; Enanta\u2019s ability to partner its RSV or other programs; Enanta\u2019s need to attract and retain senior management and key research and development personnel; Enanta\u2019s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; the outcome of the Federal Circuit rehearing petition and the Unified Patent Court proceedings related to Enanta\u2019s patent claim against Pfizer; and other risk factors described or referred to in \u201cRisk Factors\u201d in Enanta\u2019s Form 10-K for the fiscal year-ended September 30, 2025, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.<\/p>\n
Tables to Follow<\/i><\/b><\/p>\n
\n
\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n ENANTA PHARMACEUTICALS, INC.<\/b><\/td>\n<\/tr>\n \n CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<\/b><\/td>\n<\/tr>\n \n \n UNAUDITED<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n (in thousands, except per share amounts)<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n Three Months Ended<\/b><\/td>\n \n Nine Months Ended<\/b><\/td>\n<\/tr>\n \n \n June 30,<\/b><\/td>\n \n June 30,<\/b><\/td>\n<\/tr>\n \n \n \n \n\u00a0<\/p>\n<\/td>\n
\n 2026<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n 2025<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n 2026<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n 2025<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Revenue<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n14,359<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n18,314<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n50,133<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n50,199<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Operating expenses<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Research and development<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n22,126<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n27,210<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n62,428<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n82,931<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n General and administrative<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n9,469<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n9,997<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n28,046<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n34,231<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Total operating expenses<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n31,595<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n37,207<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n90,474<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n117,162<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Loss from operations<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(17,236<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(18,893<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(40,341<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(66,963<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Interest expense<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(4,130<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(1,618<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(10,529<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(5,294<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Interest and investment income, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,901<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,285<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,407<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n7,376<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Loss before income taxes<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(19,465<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(18,226<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(44,463<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(64,881<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Income tax (expense) benefit<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(36<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(29<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(67<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,692<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net loss<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n(19,501<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(18,255<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(44,530<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(63,189<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Net loss per share<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Basic<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n(0.67<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(0.85<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(1.54<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(2.96<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Diluted<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n(0.67<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(0.85<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(1.54<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(2.96<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Weighted average common shares outstanding<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Basic<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n29,090<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,377<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n28,958<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,322<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Diluted<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n29,090<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,377<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n28,958<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,322<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n \n \u00a0<\/td>\n<\/tr>\n \n ENANTA PHARMACEUTICALS, INC.<\/b><\/td>\n <\/tr>\n \n CONDENSED CONSOLIDATED BALANCE SHEETS<\/b><\/td>\n <\/tr>\n \n UNAUDITED
(in thousands)<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n June 30,<\/b><\/p>\n<\/td>\n
\n \n September 30,<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n 2026<\/b><\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n 2025<\/b><\/p>\n<\/td>\n
<\/tr>\n \n Assets<\/td>\n \n \n \n \n <\/tr>\n \n Current assets<\/td>\n \n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n33,419<\/p>\n<\/td>\n
\n \n \n \n$<\/p>\n<\/td>\n
\n \n32,298<\/p>\n<\/td>\n
<\/tr>\n \n Short-term marketable securities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n156,087<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n156,566<\/p>\n<\/td>\n
<\/tr>\n \n Accounts receivable<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,534<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,882<\/p>\n<\/td>\n
<\/tr>\n \n Prepaid expenses and other current assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n7,579<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n8,590<\/p>\n<\/td>\n
<\/tr>\n \n Total current assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n203,619<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n204,336<\/p>\n<\/td>\n
<\/tr>\n \n Long-term marketable securities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,987<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n\u2014<\/p>\n<\/td>\n
<\/tr>\n \n Property and equipment, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n31,942<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n35,395<\/p>\n<\/td>\n
<\/tr>\n \n Operating lease, right-of-use assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n35,852<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n37,549<\/p>\n<\/td>\n
<\/tr>\n \n Long-term restricted cash<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,360<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,360<\/p>\n<\/td>\n
<\/tr>\n \n Other long-term assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n110<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n92<\/p>\n<\/td>\n
<\/tr>\n \n Total assets<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n296,870<\/p>\n<\/td>\n
\n \n \n \n$<\/p>\n<\/td>\n
\n \n280,732<\/p>\n<\/td>\n
<\/tr>\n \n Liabilities and Stockholders’ Equity<\/td>\n \n \n \n \n <\/tr>\n \n Current liabilities<\/td>\n \n \n \n \n <\/tr>\n \n Accounts payable<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n3,293<\/p>\n<\/td>\n
\n \n \n \n$<\/p>\n<\/td>\n
\n \n1,948<\/p>\n<\/td>\n
<\/tr>\n \n Accrued expenses and other current liabilities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n10,183<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n12,751<\/p>\n<\/td>\n
<\/tr>\n \n Liability related to the sale of future royalties<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n36,784<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n30,710<\/p>\n<\/td>\n
<\/tr>\n \n Operating lease liabilities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,906<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,146<\/p>\n<\/td>\n
<\/tr>\n \n Total current liabilities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n54,166<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n48,555<\/p>\n<\/td>\n
<\/tr>\n \n Liability related to the sale of future royalties, net of current portion<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n88,289<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n111,132<\/p>\n<\/td>\n
<\/tr>\n \n Operating lease liabilities, net of current portion<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n51,750<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n54,757<\/p>\n<\/td>\n
<\/tr>\n \n Series 1 nonconvertible preferred stock<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,311<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,311<\/p>\n<\/td>\n
<\/tr>\n \n Other long-term liabilities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n286<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n260<\/p>\n<\/td>\n
<\/tr>\n \n Total liabilities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n195,802<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n216,015<\/p>\n<\/td>\n
<\/tr>\n \n Total stockholders’ equity<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n101,068<\/p>\n<\/td>\n
\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n64,717<\/p>\n<\/td>\n
<\/tr>\n \n Total liabilities and stockholders’ equity<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n296,870<\/p>\n<\/td>\n
\n \n \n \n$<\/p>\n<\/td>\n
\n \n280,732<\/p>\n<\/td>\n
<\/tr>\n<\/table>\n \n\u00a0<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260810427925\/en\/<\/a><\/span><\/p>\n
Media and Investors Contact:
\n<\/b>
Jennifer Viera
\n
jviera@enanta.com<\/a><\/p>\nKEYWORDS:<\/b> Massachusetts United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Other Health Health Pharmaceutical<\/p>\n
- \nEnanta\u2019s third immunology program targets MRGPRX2, a non-canonical G-Protein-Coupled-Receptor (GPCR) expressed predominantly on mast cells, as well as peripheral neurons. Inhibiting MRGPRX2 may have potential to address multiple mast-cell driven diseases, as well as having potential in migraine. Currently, the Company is evaluating multiple compounds in preclinical studies and expects to select a development candidate in the second half of 2026.<\/p>\n<\/li>\n<\/ul>\n
- \nEnanta presented posters highlighting data on EPS-3903 at the ATSInternational Conference 2026 which was held May 15-20, 2026, in Orlando, Florida and at the American Association of Immunology Conference (Immunology 2026\u2122) which was held April 15-19, 2026, in Boston, Massachusetts. The posters are available on the Company\u2019s website here<\/a>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- \nEnanta\u2019s second RSV candidate, EDP-323, can be used alone or in combination with other agents, such as zelicapavir, to potentially broaden the treatment window or addressable patient populations. Previously, the Company reported positive results from a Phase 2a challenge study of healthy adults infected with RSV, in which treatment with EDP-323 achieved highly statistically significant reductions in both viral load and clinical symptoms compared to placebo.<\/p>\n<\/li>\n<\/ul>\n
- On Track to Initiate RESOLVE, a Registrational Phase 2b\/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260810427925\/en\/1475183\/3\/Enanta_RGB.jpg\")
<\/td>\n<\/tr>\n